<DOC>
	<DOCNO>NCT01525667</DOCNO>
	<brief_summary>Local administration PLX-PAD single dose , intra-muscular injection regeneration injure gluteal musculature Total Hip Arthroplasty ( THA ) .</brief_summary>
	<brief_title>Safety Efficacy IM Injections PLX-PAD Regeneration Injured Gluteal Musculature After Total Hip Arthroplasty</brief_title>
	<detailed_description>One main problem perform THA via standard transgluteal approach necessary injury gluteus medius muscle . The consecutive decrease contractile muscle substance substitution scar tissue lead functional deficit pelvic-stabilizing musculature insufficiency limp large number patient . In long run lack musculature lead decrease bone substance insertion sit gluteal muscle proximal femur . The present study aim establish new therapy iatrogenic gluteal muscle damage . The hypothesis present proposal intra-muscular ( IM ) injection PLX-PAD iatrogenically injure gluteus medius muscle THA result improve regeneration skeletal muscle tissue consecutively improve functional outcome . Subjects assign receive one two targeted dos PLX-PAD placebo . On treatment day , suture gluteus medius muscle PLX-PAD placebo apply directly site laceration . Patients follow efficacy assessment week 26 safety assessment ( Adverse event , vital sign , ECG , routinf lab immunological testing ) week 52 THA . Patients phone week 104 order inquire occurence new cancer .</detailed_description>
	<criteria>1 . Male female subject 50 75 year age 2 . Scheduled THA 3 . ASA Score â‰¤ 3 4 . Signed write informed consent 1 . Muscle diseases 2 . Severe neurological disease 3 . Opioid long term medication 4 . Pain chronification &gt; stadium II Gerbershagen 5 . Immunosuppression due illness medication 6 . Ankylosing spondylitis 7 . History ectopic bone formation localisation 8 . Exclusion criterion MRI ( pace maker , defibrillator , ferromagnetic intracerebral clip ) 9 . Uncontrolled hypertension ( define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 200 mmHg screen ) 10 . Lifethreatening ventricular arrhythmia unstable angina characterize increasingly frequent episode modest exertion rest , worsen severity , prolong 11 . ST segment elevation myocardial infarction and/or TIA/CVA within three ( 3 ) month prior enrollment . Subjects severe congestive heart failure symptom ( i.e . NYHA Stage IV ) 12 . Subject malignancy undergo treatment include chemotherapy , radiotherapy immunotherapy 13 . Body Mass Index ( BMI ) 35 Kg/m2 great 14 . Known allergy protein product ( horse bovine serum , porcine trypsin ) use cell production process 15 . Known HIV , syphilis time screen 16 . Known active Hepatitis B , Hepatitis C infection time screen 17 . Pregnant breastfeed woman woman childbearing potential protected effective contraceptive method birth control ( define pearl index &lt; 1 ) 18 . In opinion investigator , subject unsuitable cellular therapy 19 . Subject currently enrol , yet complete period least 30 day since end investigational device drug trial ( ) 20 . Subjects legally detain official institute</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>THA</keyword>
	<keyword>Muscle injury</keyword>
</DOC>